Skip to content

Free cash flow at other companies

Eli Lilly logo
Eli LillyLLY
$3.01B+1,828%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$1.47B-56.6%
Amgen logo
AmgenAMGN
$1.48B+50.7%
AbbVie logo
AbbVieABBV
$3.56B+155%
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
-$18.16M-38.6%
Vor Biopharma logo
Vor BiopharmaVOR
-$38.29M-22.4%

Other financials

Income statement

See full
Revenue-
Operating income-$15.5M-8.0%
Net income-$14.8M-7.8%
EPS (diluted)-$0.13+51.9%

Balance sheet

See full
Cash & equivalents$90.4M+48.5%
Total debt$2.9M-9.5%
Total equity$95.8M+41.8%
Total assets$102.1M+32.3%

Cash flow

See full
Operating cash flow-$13.4M-11.6%
CapEx$63.0K

Valuation

See full
Market cap$564.45M+1,131%
Enterprise value$476.92M-4,119%
P/S564.5×+554×

Profitability

See full
Operating margin-5,266.4%-9,520pp
Net margin-4,987.4%-8,966pp
FCF margin-4,140.8%-7,144pp

Returns & leverage

See full
Return on equity-61%-8.0pp
Debt / equity0.0×
Current ratio22.1×+13.0×

Where this comes from

Calculated from Shattuck Labs, Inc.’s reported figures.

The official record: Shattuck Labs, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Shattuck Labs, Inc.'s free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Shattuck Labs, Inc.'s free cash flow?
Shattuck Labs, Inc. (STTK) reported free cash flow of -$13.49M in Q1 2026.
How has Shattuck Labs, Inc.'s free cash flow changed year-over-year?
Shattuck Labs, Inc.'s free cash flow decreased by 12.1% year-over-year, from -$12.03M to -$13.49M.
What is the long-term trend for Shattuck Labs, Inc.'s free cash flow?
Over 4 years (2021 to 2025), Shattuck Labs, Inc.'s free cash flow has grown at a -11.5% compound annual growth rate (CAGR), from -$65.04M to -$39.95M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.